Barbro Fridén steps down as a member of the board of Vitrolife AB (publ)

Barbro Fridén has decided to step down as a member of the board of Vitrolife AB due to other future opportunities. Barbro Fridén has been a member of the board of Vitrolife since 2010. “We thank Barbro Fridén for contributing to Vitrolife's success with great commitment and expertise”, says Jón Sigurdsson, chairman of the board.

Gothenburg, November 18, 2019

VITROLIFE AB (publ)

Contact:
Jón Sigurdsson, Chairman of the Board, email: jsigurdsson@ossur.com
Mikael Engblom, CFO, phone 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.00 pm CET on November 18, 2019. 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/